Repaglinide
|
|
|
- CAS-Nr.
- 135062-02-1
- Englisch Name:
- Repaglinide
- Synonyma:
- PRANDIN;Repaglinide API;EP5.2;CS-1998;NOVONORM;AG-EE-623;ag-ee388zw;Repaglinid;Rapaglinide;Rebaglinide
- CBNumber:
- CB4140539
- Summenformel:
- C27H36N2O4
- Molgewicht:
- 452.59
- MOL-Datei:
- 135062-02-1.mol
|
Repaglinide Eigenschaften
- Schmelzpunkt:
- 129-130.2 °C
- alpha
- D20 +6.97° (c = 0.975 in methanol); D20 +7.45° (c = 1.06 in methanol)
- Siedepunkt:
- 672.9±55.0 °C(Predicted)
- Dichte
- 1.137±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- Löslichkeit
- DMSO: 34 mg/mL
- Aggregatzustand
- solid
- pka
- 4.19±0.10(Predicted)
- Farbe
- white
- Wasserlöslichkeit
- 89.99mg/L(25 ºC)
- Merck
- 14,8136
- InChIKey
- FAEKWTJYAYMJKF-QHCPKHFHSA-N
- SMILES
- C(O)(=O)C1=CC=C(CC(N[C@H](C2=CC=CC=C2N2CCCCC2)CC(C)C)=O)C=C1OCC
- CAS Datenbank
- 135062-02-1(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| WGK Germany |
2 |
|
|
| RTECS-Nr. |
000000033825 |
|
|
| HS Code |
2933399090 |
|
|
| Toxizität |
LD50 orally in rats: >1 g/kg (Grell) |
|
|
| Bildanzeige (GHS) |
 
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H361 |
Kann vermutlich die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen. |
Reproduktionstoxizität |
Kategorie 2 |
Warnung |
|
P201, P202, P281, P308+P313, P405,P501 |
| H362 |
Kann Säuglinge über die Muttermilch schädigen. |
Reproductive toxicity, effects on or via lactation |
Additional category |
|
|
P201, P260, P263, P264, P270,P308+P313 |
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
| P260 |
Dampf/Aerosol/Nebel nicht einatmen. |
| P263 |
Kontakt während der Schwangerschaft /und der Stillzeit vermeiden. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P308+P313 |
BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
|
Repaglinide Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Repaglinide was marketed in the US as an orally active hypoglycemic
agent in patients with a type Ⅱ diabetes mellitus, to lower blood glucose in
synergistic combination with metformin, when hyperglycemia cannot be
controlled by diet, exercise or metformin alone. Chiral (S)-repaglinide can be
synthesized in several ways, each involving a stereoselective reduction of an
imine or enamine group. Repaglinide is a nonsulfonylurea belonging to the
meglitinide family, with an insulin-releasing effect mediated by pancreatic betacells,
by closing the ATP-sensitive K+ channels that, in turn, increases the
cytosolic concentration of Ca++. In several animal models, repaglinide was more
efficient than glibenclamide as a dose-dependant promoter of insulin release,
but its mechanism of action is probably slightly different. Repaglinide has a rapid
onset of action, a short duration of action and a reduced risk of hypoglycemia
compared to glyburide.
Chemische Eigenschaften
White to Off-White Solid
Verwenden
The R-enantiomer showed only weak hypoglycemic activity. Repaglinide impurity
Allgemeine Beschreibung
Repaglinide is 2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid(Prandin); approvals for generics are pending. Combinationsare available with metformin in the United States(Prandimet), and the drug may also be coprescribed with oneof the thiazolidinediones (typically pioglitazone or rosiglitazone;see previous discussion). To establish the most clinicallyvaluable dose, the patient is titrated while monitoringblood glucose levels and hemoglobin glycosylation (HbA1c)as an index of longer-term overall control.
Biologische Aktivität
K ATP channel blocker that binds with high affinity for SUR1 when co-expressed with Kir6.2 (K d = 0.42 nM). Antidiabetic glucose regulator with hypoglycaemic effect in vivo .
Clinical Use
Repaglinide is a nonsulfonylurea insulin secretagogue that was introduced in the United States in 1998 for type 2 diabetes.
Repaglinide Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Repaglinide Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 627)Lieferanten
135062-02-1()Verwandte Suche:
- AG-EE-623 ZW
- (S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid
- Repaglinide,(S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid, Novonorm, Prandin
- Repaglinide (200 mg)G0D2760.999mg/mg(ai)
- Repaglinide (200 mg)
- (S)-2-Ethoxy-4-[2-[[[(1S)-3-Methyl-1-[2-(1-piperidinyl)phenyl]butyl]aMino]-2-oxoethyl]benzoic Acid
- Repaglinide(AG-EE 623ZW)
- Rebaglinide
- 2-ethoxy-4-({[(1S)-3-Methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbaMoyl}Methyl)benzoic acid
- Rapaglinide
- Repaglinde Solution, 100ppm
- AG-EE-623
- 2-ETHOXY-4-[2-[(1S)-3-METHYL-1-[2-(1-PIPERIDINYL)BUTYL]AMINO]-2-OXOETHYL]-BENZOIC ACID
- REPAGLINIDE
- (S)-2-ETHOXY-4-(2-(3-METHYL-1-(2-(PIPERIDIN-1-YL)PHENYL)BUTYLAMINO)-2-OXOETHYL)BENZOIC ACID
- (S)-(+)-2-ETHOXY-4-[N-[1-(2-PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYLMETHYL]BENZOIC ACID
- NOVONORM
- (S)-(+)-2-Ethoxy-4-[[[N-[1-(2-piperidinophenyl)-3-methylbutyl]amino]carbonyl]methyl]benzoic acid
- Benzoic acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)- 2-oxoethyl)-, (S)-
- 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
- 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxo-ethyl]benzoic acid
- 2-ethoxy-4-[2-keto-2-[[(1S)-3-methyl-1-(2-piperidinophenyl)butyl]amino]ethyl]benzoic acid
- ag-ee388zw
- Prandin, 2-Ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)butyl]amino]-2-oxoethyl]-benzoic Acid, AG-EE-623, Novonorm,
- S(+)-2-Ethoxy-4-(2-oxo-2-((alpha-isobutyl-2-piperidinobenzyl)amino)ethyl)benzoesure
- 2-Ethoxy-4-[2-[[(1R)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid
- AG-EE 624ZW
- 4-Carboxy-3-ethoxybenzeneacetic Acid
- 2-Ethoxy-4-[2-[[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid
- Novonorm, Prandin, (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid
- 2-ethoxy-4-[2-[[3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
- EP5.2
- CS-1998
- (S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid
- Repaglinide CRS
- Repaglinide>
- Repaglinide for system suitability CRS
- Benzoic acid, 2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-
- Repaglinide USP/EP/BP
- RepaglinideQ: What is
Repaglinide Q: What is the CAS Number of
Repaglinide Q: What is the storage condition of
Repaglinide Q: What are the applications of
Repaglinide
- Repaglinide (1600813)
- Repaglinide,(S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid, Novon
- Repaglinide API
- PRANDIN
- Benzenemethanol,α-(aminomethyl)-8-bromo-
- methyl 3-[4-cyano-4-[phenyl(propanoyl)amino]piperidin-1-yl]propanoate
- Repaglinid
- Repaglinde Reference Standard
- 135062-02-1
- 35062-02-1
- 135062-02-6
- C27H36N2O4
- Pharmaceutical raw material
- DTIC-DOME
- API
- Aromatics
- Heterocycles
- Amino Acids 13C, 2H, 15N
